Evaluation of Orlistat as Adjuvant Treatment of Obesity in Adults

A Prospective Study, Parallel, Double-blind, Multicenter for Evaluation of Efficacy of Orlistat 60 mg as Adjuvant Treatment of Obesity in Adults

The purpose of this study is to evaluate efficacy of orlistat 60 mg as adjuvant treatment of Obesity in adults.

Inclusion Criteria:

• Signed Informed Consent;
• Adults Male and Female ≥ 18 years old;
• Obesity (BMI ≥ 30kg/m2 or ≥ 27 Kg/m2 with associate risk);

Exclusion Criteria:

• Pregnancy and Lactation or women without effective contraception;
• Relevant clinical diseases;
• Obesity associated to genetic syndrome;
• Decompensated Diabetes;
• Psychiatric disorders;
• Alimentary disorders;
• Use of: anorectics, herbal weight loss and/or constipation and laxatives, in the past 30 days;
• Patients using cyclosporine or amiodarone;
• Patients with bowel disease;
• Prior bariatric surgery;
• Anemia;
• Hemoglobinopathies and coagulopathy;
• History of cancer in the past five years;
• Use of corticosteroids, oral or injectable, in the last 30 days.